Navigation Links
New research model of human prostate cancer shows cancer development
Date:7/1/2010

Progress toward understanding the role of sex hormones in the growth of prostate cancerthe most common cancer in U.S. menhas been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.

Their results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

"We hope this model will speed up the process of testing preventive therapies for prostate cancer as well as help clarify the hormonal mechanisms in the development of this cancer," said Gail Prins, PhD, a professor and reproductive physiologist at the University of Illinois at Chicago, who is a co-author of the study.

"Sex hormonestestosterone and estrogensare involved in regulating the growth of prostate cancer, but the mechanisms are not well established," Prins said.

Currently the only available laboratory models of human prostate cancer are xenograftscancerous human tissues grafted under the skin of animalsor "transformed" cancer cell lines containing cells that originally came from patients with prostate cancer. However, Prins said, "If you want to study the initial development of cancereither naturally or inducedor its prevention, you cannot use a model of existing cancer, such as transformed cell lines."

To study the progression of prostate cancer from normal cells into cancerous cells requires the use of animal prostate cells. Animal models, however, do not directly mimic all aspects of human prostate cancer, experts say.

Prins and her colleagues created their model using prostate cells obtained from a deceased organ donor who did not have prostate disease. They isolated and grew, in 3-D culture, adult prostate progenitor cellscells with stem cell-like properties that self-renew and may become cancerous. In 3-D culture, the progenitor cells proliferate and form small spheroids, called prostasphere
'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Parkinson's Disease Patient Tells Personal Story to Benefit PD Research; Donates Book Proceeds to PD Charities
2. Parkinsons Transplant Mystery Solved, Researchers Say
3. BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation
4. Scripps Research scientists share $2 million in Florida state research grants
5. Psychological research conducted in WEIRD nations may not apply to global populations
6. Researchers suggest new paradigm for breast cancer screening
7. Hebrew University added to Singapore research program
8. Sheldon Manufacturing, Inc. Announces New Ergonomic Bactron Anaerobic Chamber For Microbiology Research
9. Of lice and man: Researchers sequence human body louse genome
10. AcademyHealth honors leading health services researchers
11. APS urges greater federal investment in energy research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... of developing celiac disease isn,t reduced by breast-feeding. Nor will ... gluten to an infant,s diet help prevent celiac disease. ... studies in the Oct. 2 New England Journal of ... that a child could avoid celiac disease if mothers breast-feed ...
(Date:10/1/2014)... researchers from the University of Adelaide have developed a ... of a good outcome from treatment - from their ... on a range of factors, including clinical symptoms, cognitive ... in the patient,s blood. , Speaking in the lead ... University,s Head of Psychiatry , Professor Bernhard ...
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog ... couples. , Senior citizens can purchase a joint ... loved ones. A joint policy is cheaper, but will ... , Life insurance can be used to cover ... be purchased online, as the application process is simple ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
Breaking Medicine News(10 mins):Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... , , TAMPA, Fla. ... Solutions, today announced the appointment of Michael Unhjem as a member of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090709/FL43703LOGO ) , ... of Blue Cross Blue Shield (BCBS) of North Dakota, was unanimously elected ...
... SEATTLE, July 20 Group Health Cooperative medical centers received ... the Puget Sound Health Alliance Community Checkup . Group ... nine medical groups in the Puget Sound region that were rated on ... regional average" scores. , , "We support ...
... , MINNEAPOLIS, July 20 ... into a business relationship with Cardiocom(R) to provide advanced home ... Experts in Telehealth(SM), is a world class developer, manufacturer and ... , Cardiocom,s telehealth system provides an interactive ...
... 20 N y comed tod a y announced t h e su b mission of a N e ... n d Drug Administr a tion ( F DA) for ... oral treatme n t for patie n t s ... i ssion is ba s e d on enc ou raging result s fro m ...
... , , ... DIEGO, July 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today ... its investigational drug for the treatment of obesity, met their co-primary endpoints. ... O besity R esearch, or COR, program of more ...
... , , ... -- Allscripts (Nasdaq: MDRX ) announced today ... Human Resources. Ms. Adams brings to the position more than 20 ... high tech industry, most recently as Vice President of Human Resources ...
Cached Medicine News:Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 2Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 3Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Silas Home Care Selects Cardiocom Telehealth Technology 2Health News:Nycomed Announces FDA Filing for Daxas(R) in COPD 2Health News:Nycomed Announces FDA Filing for Daxas(R) in COPD 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 2Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 3Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 4
(Date:10/2/2014)... Intarcia Therapeutics, Inc. today announced successful top-line results ... for ITCA 650 (exenatide, delivered continuously once or twice ... trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical ... 650 in patients with type 2 diabetes against placebo. ... to placebo for both 40 mcg and 60 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a ... used to develop and produce enzymes and other ... industrial enzymes industries, today announced the receipt of ... commercial scale production of Abengoa,s proprietary cellulase enzymes, ... Abengoa,s license agreement with Dyadic. ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... the worldwide leader in handheld x-ray technologies, has been ... Edison Best New Product Awards™. The winners were announced ... ballroom in New York City.  The NOMAD® Handheld X-ray ... Medical Handheld or Miniaturized Devices Segment. ...
... PRA International, a leading Clinical Research Organization, announces that ... will speak at the World Drug Safety Congress being held ... host an exhibit at booth #2. Dr. ... first breakout stream, "Operational Safety," on 13 April at 1:50 ...
Cached Medicine Technology:NOMAD by Aribex Receives Edison Best New Product Award 2PRA International Experts to Speak at Drug Safety Conference 2
3 mm disposable bevel blades. Malleable shafts. Blades packaged 6 per package....
Straight 8 mm downcutting Royce blade. Can be placed in closed handle for protection. Rigid handle when folded and locked. Straight 8 mm downcutting blades. Handle length folded 109 mm, 4.3 inches....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: